Summary of Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings on May 17, 2018

May 17, 2018 - By Jason Dias

Theravance Biopharma, Inc. (NASDAQ:TBPH) Corporate Logo
Big Money Sentiment decreased to 1.31 in Q4 2017. It has change of 0.01, from 2017Q3’s 1.32. The ratio dropped due to Theravance Biopharma, Inc. positioning: 7 sold and 22 reduced. 12 funds acquired holdings and 26 increased holdings. Investors holded 35.46 million in 2017Q3 but now own 35.06 million shares or 1.11% less.
Moreover, Alliancebernstein Lp has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 61,235 shs. Invesco invested in 7,311 shs or 0% of the stock. Envestnet Asset Mgmt reported 323 shs. American Int Gru invested in 0% or 28,134 shs. Natl Bank Of Montreal Can stated it has 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Nj State Employees Deferred Compensation Plan holds 34,142 shs or 0.16% of its capital. Bnp Paribas Arbitrage stated it has 0% of its capital in Theravance Biopharma, Inc. (NASDAQ:TBPH). 512,042 were accumulated by Northern. Panagora Asset Mgmt Inc holds 0% of its capital in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 3,111 shs. Maryland-based Proshare Advisors Limited Liability Corporation has invested 0.01% in Theravance Biopharma, Inc. (NASDAQ:TBPH). 19,434 are owned by Parametric Port Assoc Ltd Liability Co. State Of New Jersey Common Pension Fund D invested in 225,459 shs. Parallax Volatility Advisers Limited Partnership reported 6,384 shs stake. Tower Ltd Liability Com (Trc) reported 546 shs or 0% of all its holdings. Rock Springs Mngmt L P holds 0.83% or 652,600 shs.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

In total 3 analysts cover Theravance Biopharma (NASDAQ:TBPH). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:TBPH) has 100% bullish analysts. 4 are the (NASDAQ:TBPH)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Thursday, March 29 the company was initiated by Piper Jaffray. On Tuesday, February 27 the company was maintained by Cantor Fitzgerald. On Tuesday, May 8 the stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) has “Buy” rating given by Cantor Fitzgerald. On Thursday, February 8 the firm earned “Outperform” rating by Leerink Swann. Listed here are Theravance Biopharma, Inc. (NASDAQ:TBPH) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0000 Maintain
29/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $45.0000 Initiate
27/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0 Maintain
08/02/2018 Broker: Leerink Swann Rating: Outperform Old Target: $45 New Target: $48 Maintain

TBPH is hitting $24.35 during the last trading session, after decreased 1.30%.Currently Theravance Biopharma, Inc. is downtrending after 26.76% change in last May 17, 2017. TBPH has also 175,081 shares volume. The stock underperformed the S&P500 by 38.31%.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics.The firm is valued at $1.34 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.Currently it has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

More recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were brought out by Streetinsider.com, Seekingalpha.com and Prnewswire.com. The first one has “Theravance Biopharma (TBPH) Announces Approval of Expanded Indication in US for Once-Daily Trelegy Ellipta for …” as a title and was brought out on April 25, 2018. The next is “Theravance Biopharma’s (TBPH) CEO Rick Winningham on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. And last was brought out on April 20, 2018, called “Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical …”.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.